Royalty Report: Medical, Device, Surgical – Collection: 3938


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Medical
  • Device
  • Surgical
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3938

License Grant
U.S. Corp. announced that a federal U.S. district court jury in San Francisco awarded it past damages and on-going royalties, finding that another U.S. corporation's manufacture, sale and use of its Amplatzer®Occluder and vascular plug product lines infringed claims of two U.S. patents owned by licensor.
License Property
The patents involved in this case are U.S. Patent No's. 6,306,141 and 5,067,957, known as the Jervis patents. The 141 patent covers self-expanding medical devices using stress to restrain a metal alloy that will expand to its original shape upon being released from a restraint, such as a sheath. For example, this invention allows doctors to locate and expand a medical device to repair holes in the heart, treat aortic aneurysms, place stents within the peripheral vasculature or treat damaged or diseased heart valves via a less invasive, transcatheter heart valve procedure. The 957 patent, which expired in 2004, covers a method of treatment using shape memory alloys, such as nitinol, in accordance with the Jervis inventions.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 6202

License Grant
The Licensor, an individual, assigned the patents for his inventions to certain pediatric cardiology medical devices and techniques and know-how to the Licensee.
License Property
Our Amplatzer occlusion devices offer minimally invasive, transcatheter treatments that have been clinically shown to be highly effective in defect closure.

Our AMPLATZER occlusion devices utilize our expertise in braiding nitinol, a metal alloy with superelastic and shape-memory characteristics, and designing transcatheter delivery systems.

IPSCIO Record ID: 5941

License Grant
Licensee acquired the exclusive rights to the CardioSEAL® cardiac septal repair implant from the Licensor, a non-profit health care organization.   In connection with this acquisition, the Licensee acquired all of the existing development, manufacturing, testing equipment, patent Licenses, know-how and documentation necessary to manufacture cardiac septal repair implant devices. Under the License Agreements, as amended, the Licensee pays royalties to the Licensor on all commercial sales of our cardiac septal repair products. The Territory for sales of CardioSEAL® is the United States, Canada and Europe. The Licensee sells STARFlex® in Europe.
License Property
CardioSEAL® and STARFlex® are revolutionary products designed to close different types of holes in the heart without open heart surgery.  CardioSEAL®, a third generation implant, is constructed from a low profile, metal framework shaped like an umbrella to which a knitted polyester fabric is securely attached. CardioSEAL is comprised of two of these umbrellas, one for each side of the septum. Both the metal and fabric are made from the most biocompatible materials known for this application. The framework in particular has been selected for its excellent biocompatibility profile. After all, this implant will be in place for the life of the patient.

The Licensee has an exclusive worldwide License from the Licensor under United States patents entitled Occluder and Method for Repair of Cardiac and Vascular Defects (U.S. Patent No. 5,425,744), Occluder for Repair of Cardiac and Vascular Defects (U.S. Patent No. 5,451,235) and Self-Centering Umbrella-Type Septal Closure Device (U.S. Patent No. 5,709,707) and the respective corresponding foreign patents, patent applications and associated know-how.

Field of Use
The rights granted apply to cardiac products.

IPSCIO Record ID: 29104

License Grant
The Licensee has entered into an agreement with the Licensor, an individual, who shall provide technical assistance to the Licensee upon request,  to enable the Licensee to manufacture and market the Products or the Licensor's improvements thereto and to prosecute and enforce any Patent Rights.
License Property
The royalty obligations shall continue in full force for as long as the vascular graft, vascular plug, or vascular trap is covered by, or manufactured in accordance with the method recited in, one or more valid and enforceable claims of a patent issuing from or claiming priority to U.S. Patent No. 6,123,715.

IPSCIO Record ID: 2991

License Grant
Trial in the Company's U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October 2007 with a jury finding that the patent was invalid. The licensee was found to infringed a patent covering features of the chemically treated and multi-layered guide wire tubes that enable catheters to slide into place. The jury also found for patent owner on its counterclaim that sale by the Company of its balloon catheters and stent delivery systems infringe owner's Fontirroche patent. The Court has denied the Company's post trial motions.
License Property
Fontirroche patents pertain to designs for balloon catheters and stent delivery systems.

IPSCIO Record ID: 6158

License Grant
The Licensee and the Licensors, two individuals, entered into a worldwide License agreement for  the Invention, including without limitation the entire right, title and interest to the Patent Rights to the  Atrial Septal Defect (ASD) and a Patent Ductus Arteriosus (PDA) Device Percutaneous Catheter Directed Intravascular Occlusion Devices – US Patent 5725552 .  The agreement shall continue in full force and effect for the commercial life of all products covered under this Agreement unless otherwise terminated. Inventors also grant the Licensee the exclusive right, but not the obligation, to use one or all of the inventors, names in its name or trademark for any Products and to use one or all of the inventors’ names in connection with the advertising and marketing of Products.  Intra-cardiac devices are used in various medical procedures
License Property
Atrial septal defect (ASD) is a form of congenital heart defect that enables blood flow between two compartments of the heart called the left and right atria.
Patent ductus arteriosus (PDA) is a congenital disorder in the heart wherein a neonate's ductus arteriosus fails to close after birth.

IPSCIO Record ID: 3489

License Grant
The Company announced today that it received a ruling from the U.S. District Court in regards to ongoing royalty rates for Phase I of its patent litigation with Plaintiff. As previously announced, Phase 2 surrounding the cervical plates involved in the dispute was settled.
License Property
On August 17, 2012, Plaintiff filed additional patent claims in the U.S. District Court for the Northern District of Indiana alleging that the Company various spinal implants (including its CoRoent® XL family of spinal implants) infringe U.S. Patent No. 8,021,430, and that the Company's Osteocel® Plus bone graft product infringes U.S. Patent No. 5,676,146 C2. On August 28, 2012, Plaintiff amended its complaint in the Northern District of Indiana alleging that NuVasive's XLIF® procedure and use of MaXcess IV retractor during the XLIF procedure infringe methodology claims of U.S. Patent No. 8,251,997.
Field of Use
The CoRoent XL is a family of spinal implants used to replace weakened or damaged intervertebral discs. These discs act as the spine’s shock absorber allowing forces to be distributed evenly during the body’s movements.

And MaXcess instruments provide access to the spine in a manner that affords direct visualization and our nerve monitoring systems assist surgeons in avoiding critical nerves.  Our MaXcess system consists of instrumentation and specialized implants that provide maximum access to the spine with minimal soft tissue disruption. MaXcess has a split blade design consisting of three blades that can be positioned to build the surgical exposure in the shape and size specific to the surgical requirements rather than the fixed tube design of other minimally invasive surgical systems. MaXcess’ split blade design also provides expanded access to the spine, which allows surgeons to perform surgical procedures using instruments that are similar to those used in open procedures but with a significantly smaller incision. The ability to use familiar instruments reduces the learning curve and facilitates the adoption of our products. Our system’s illumination of the operative corridor aids in providing surgeons with direct visualization of the patient’s anatomy, without the need for additional technology or other special equipment.

IPSCIO Record ID: 336324

License Grant
Licensor has been advised that Licensee will assign the Patent Sublicense Agreement to a new Licensee. The assignment provisions of the Sublicense Agreement shall continue in full force with changes to the royalty amount.

Per the Patent Sublicense Agreement,, Licensor hereby grants to Licensee a personal, nonexclusive sublicense under the Sublicensed Patent to make, have made for its own account, use, and import Licensed Products, and to sell, lease, offer for sale and otherwise transfer Licensed Products as hereinafter provided. Licensee or an Affiliate of Licensee may sell or transfer Licensed Products directly to End Users. Licensee or, in the event that Licensee first sells or transfers Licensed Products to any Affiliate of Licensee, such Affiliate, may also sell or transfer Licensed Products to Distributors for resale to End Users; provided, however, that any such Distributor must resell the Licensed Products to End Users in unchanged form, and provided further, that there shall be no more than one distribution channel for Licensed Products (i.e., one of Licensee or an affiliate of Licensee or a Distributor) in any specific country in the world. This sublicense specifically excludes any right of Licensee (or any Affiliate or Distributor of Licensee) to sell or otherwise transfer Licensed Products to OEM Customers.

License Property
Sublicensed Patent shall mean United States Patent No. 6,436,135 issued to David Goldfarb, MD. on August 20, 2002, and any reissues and/or any reexaminations thereof.
United States Patent No. 6,436,135 – Prosthetic vascular graft
Field of Use
The Licensee's EndoFit Aortic Stent Graft is a line of endovascular grafts used to treat aortic aneurysms, a weakening and ballooning of the aorta.

Field of Use shall mean the field of endovascular products i.e., medical products that are placed within the arteries or veins of the human body. The Field of Use expressly excludes any surgical prosthetic device intended in whole or in part to replace any portion of any artery, vein or other vessel or conduit within the human body, including but not limited to bypass grafts, dialysis grafts, aortic grafts or thoracic grafts.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.